LivaNova (NASDAQ:LIVN) Stock Rating Upgraded by StockNews.com

LivaNova (NASDAQ:LIVN) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Tuesday.

LIVN has been the topic of several other research reports. Barclays reduced their price objective on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research note on Friday, March 7th. The Goldman Sachs Group reduced their price target on LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. Stifel Nicolaus reduced their target price on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Finally, Needham & Company LLC reissued a “buy” rating and set a $64.00 target price on shares of LivaNova in a research report on Monday, March 17th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $61.17.

LivaNova Trading Down 1.1 %

LIVN traded down $0.45 during trading on Tuesday, reaching $39.92. 458,433 shares of the company’s stock were exchanged, compared to its average volume of 595,299. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova has a one year low of $36.85 and a one year high of $64.48. The firm has a fifty day moving average price of $45.01 and a two-hundred day moving average price of $48.65. The stock has a market capitalization of $2.17 billion, a PE ratio of 95.05 and a beta of 1.10.

Hedge Funds Weigh In On LivaNova

A number of institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. increased its stake in shares of LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after acquiring an additional 219 shares in the last quarter. Sterling Capital Management LLC increased its stake in LivaNova by 800.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock valued at $75,000 after purchasing an additional 1,441 shares in the last quarter. Central Pacific Bank Trust Division raised its holdings in shares of LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock valued at $191,000 after purchasing an additional 720 shares during the period. Vestcor Inc bought a new position in shares of LivaNova during the 4th quarter worth about $204,000. Finally, Optimize Financial Inc acquired a new stake in shares of LivaNova in the 4th quarter valued at about $208,000. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.